A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Everolimus for the Prevention of BK and CMV Viremia in HLA Sensitized Kidney Transplant Recipients

Trial Profile

A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Everolimus for the Prevention of BK and CMV Viremia in HLA Sensitized Kidney Transplant Recipients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Everolimus (Primary) ; Tacrolimus
  • Indications Cytomegalovirus infections; Polyomavirus infections; Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2016 Planned End Date changed from 1 Jun 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
    • 08 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 06 May 2015 Interim results (n= 18) presented at the 2015 American Transplant Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top